Mivavotinib monohydrochloride (Standard)

Overview

Mivavotinib (monohydrochloride) (Standard) is the analytical standard of Mivavotinib (monohydrochloride) ( HY-100867A ). This product is intended for research and analytical applications. TAK-659 hydrochloride is a highly potent, selective, reversible and orally available dual inhibitor of spleen tyrosine kinase ( SYK ) and fms related tyrosine kinase 3 ( FLT3 ), with an IC50 of 3.2 nM and 4.6 nM for SYK and FLT3 , respectively. TAK-659 hydrochloride induces cell death in tumor cells but not in nontumor cells, and with potential for the treatment of chronic lymphocytic leukemia (CLL).

Application

Products | Products > Signaling Pathways > Others | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Reference Standards | Products > Signaling Pathways > Syk | Products > Signaling Pathways > FLT3

Product Information

• Catalog No.: HY-100867AR
• CAS No.: 1952251-28-3
• Molecular Formula: C17H22ClFN6O
• Molecular Weight: 380.85
• Purity: 98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source